← Back to GLP-3 product page
How to read this GLP-3 / G3 research page
This page summarizes published GLP-3 / LY3437943 literature by experimental theme, including receptor binding, cell-based signaling, glucagon-receptor pathway context, and multi-receptor design. It is a literature map for research documentation, not a protocol or human-use resource.
- Search terminology: GLP-3, G3 peptide, G3R, G3-R, Triple-G, and LY3437943 may refer to the same research-compound family in catalog and literature searches.
- Mechanistic scope: summaries focus on receptor-assay and preclinical research design, not product claims or intended uses.
- Documentation links: compare the GLP-3 catalog listing, COA hub, y research framework.
Panda Peptides products are for research use only. No dosing, administration, reconstitution, treatment, or human-use guidance is provided.
Biblioteca de investigación
Published research on this compound — for educational purposes only
How does GLP-3 engage three receptor types simultaneously? (for educational purposes only)
GLP-3 (LY3437943) is a single peptide engineered to activate GIP, GLP-1, and glucagon receptors through distinct structural domains within one alpha-helical chain. The peptide backbone incorporates sequence elements from all three native ligands, with the N-terminal region primarily driving glucagon and GLP-1 receptor activation and mid-chain residues contributing to GIP receptor engagement. A C-20 fatty diacid moiety enables albumin binding for extended half-life. In cell-based assays, GLP-3 demonstrates agonist activity at all three receptors with engineered potency ratios. For laboratory research use only.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
What does the glucagon receptor component contribute to GLP-3’s pharmacology? (for educational purposes only)
The glucagon receptor (GCGR) agonist component distinguishes GLP-3 from dual GIP/GLP-1 agonists. Glucagon receptor activation in preclinical models has been associated with increased hepatic lipid oxidation and elevated energy expenditure through thermogenic pathways. In cell-based assays, GLP-3 activates GCGR-mediated cAMP signaling, engaging hepatic metabolic pathways distinct from those activated by GLP-1R or GIPR. The inclusion of GCGR agonism creates a pharmacological profile not achievable with mono- or dual-agonist compounds, engaging liver, pancreas, and adipose tissue receptor populations simultaneously. For laboratory research use only.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
How does GLP-3 compare structurally to dual agonists like GLP-2 T? (for educational purposes only)
While GLP-2 T engages two receptors (GIP and GLP-1), GLP-3’s peptide sequence was engineered to additionally activate the glucagon receptor — requiring incorporation of glucagon-derived residues not present in dual agonist designs. Both compounds share lipidation strategies (C-20 fatty diacid for albumin binding) and DPP-4 resistance modifications, but GLP-3’s sequence diverges substantially to accommodate three-receptor cross-reactivity within a single linear peptide. The structural challenge of maintaining potency at three distinct class B GPCRs simultaneously required extensive sequence optimization. For laboratory research use only.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
What is GLP-3’s receptor potency profile across GIP, GLP-1, and glucagon receptors? (for educational purposes only)
In vitro characterization demonstrates that GLP-3 activates all three target receptors with distinct potency ratios. The compound shows highest relative potency at the GIP receptor, followed by GLP-1R, with moderate but pharmacologically relevant GCGR agonism. EC₅₀ values for cAMP accumulation at each receptor have been characterized in HEK293 cells expressing human receptors. The intentional potency imbalance — strongest at GIPR, intermediate at GLP-1R, and lowest at GCGR — was engineered to balance the overall receptor activation profile during preclinical characterization. For laboratory research use only.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
To compare published studies with Panda batch documentation, review Reportes de laboratorio (COAs), Calidad y pruebas, la guía para evaluar materiales de investigación, o nuestras Preguntas frecuentes.
Continue reviewing GLP-3
Use the research references above alongside Panda’s batch documentation and catalog specifications.
Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.
Reviewed by
James S.
Research content reviewer focused on peptide literature summaries, source quality, and reference clarity.
Reviewed by Elizabeth D. y James S. — Panda Peptides Research Team.
Last reviewed: June 2026.
This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for controlled laboratory, analytical, or reference use and are not consumer products.
